Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
15.80 410.98 0.00 0.00

+8 more quarters

P/S ratio
3.31 2.64 2.43 1.92
P/FCF ratio
10.75 37.30 32.79 21.00
P/Operating CF
36.64 28.67 28.60 16.85
P/B ratio
3.17 2.58 2.40 2.02
EV/Sales
3.78 3.20 3.11 2.72
EV/EBITDA
10.76 21.01 49.93 59.08
EV/FCF
12.27 45.21 42.02 29.70
Current Ratio
1.78 2.04 1.86 1.65
Net Debt/EBITDA
5.04 4.79 6.72 14.06
Debt/Equity
0.91 1.18 1.24 1.35
Earnings Yield
6.33% 0.24% (3.41%) (4.52%)
Free Cash Flow Yield
9.30% 2.68% 3.05% 4.76%
Free Cash Flow per Share
5.07 6.28 5.26 6.38
Book value per Share
75.98 73.22 70.82 65.23
Free Cash Flow
320.60 388.50 320.46 386.98
EV/EBIT
19.38 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates